论文部分内容阅读
本实验研究了双苄基异喹啉类生物碱小檗胺（Ｂｅｒｂａｍｉｎｅ）对人中性粒细胞血小板激活因子（ＰＡＦ）的产生及ＰＡＦ引起的兔血小板聚集的影响，并与钙通道阻断剂维拉帕米进行比较。结果表明，小檗胺（５０μｍｏｌ／Ｌ，１００μｍｏｌ／Ｌ）和维拉帕米（１０μｍｏｌ／Ｌ，１００μｍｏｌ／Ｌ）预处理的人粒细胞，用Ａ－２３１８７攻击后，ＰＡＦ的产生明显降低。小檗胺和维拉帕米也能抑制ＰＡＦ（７０ｐｍｏｌ／Ｌ）引起的血小板聚集，其抑制作用呈剂量依赖性。本实验结果提示，小檗胺和维拉帕米对ＰＡＦ生成及血小板聚集的抑制作用可能与阻断钙离子内流有关。
In this study, we investigated the effects of bibenzyl isoquinoline alkaloid Berbamine on the production of human neutrophil platelet activating factor (PAF) and platelet aggregation induced by PAF in rabbits, and compared with calcium channel blockers Verapamil for comparison. The results showed that the production of PAF was significantly decreased in human granulocytes pretreated with berbamine (50μmol / L, 100μmol / L) and verapamil (10μmol / L, 100μmol / L) Berbamine and verapamil also inhibited platelet aggregation induced by PAF (70 pmol / L) in a dose-dependent manner. The results suggest that berbamine and verapamil inhibition of PAF generation and platelet aggregation may be related to blocking the influx of calcium ions.